The aim of the present study is development and characterization of selfnanoemulsifying drug delivery systems (SNEDDSs) to improve the rate of dissolution of poorly water soluble anti-platelet agent clopidogrel bisulfate. The solubility was estimated in various vehicles to select proper components and compositions. Cinnamon oil (as oil), Tween 80 (as surfactant), polyethylene glycol 400 (as co-surfactant) and Water is used to construct pseudo-ternary phase diagrams. Stability, dispersibility and robustness to dilution were performed to optimize formulations by using phase diagram. Formulations were prepared with different composed of cinnamon oil, Tween 80 and PEG 400 (S mix ) ratios. The globule size of the optimized system was less than 200 nm which could be an accepted nanoemulsion size range. The selected formulation F 7 SNEEDS of z-average size was 140.8 nm and zeta potential was -28.6. In vitro drug release studies showed signi icantly enhanced rate of dissolution of F 7 SNEDDS when compared to the marketed formulation.
INTRODUCTION
Newly developed drug candidates (almost 40%) are practically water insoluble drugs (PWSD). These API's poses several problems while developing dosage forms and water insolubility implicates in low bioavailability (Dokania and Joshi, 2015; Patel et al., 2010) Currently researchers are developing dosage form to increase the solubility in the gastrointestinal tract and support drug exposure after oral administration (Zanchetta et al., 2009) These are the formulations developed to increase the bioavailability of PWSD salt formulation (Serajuddin, 2007) , micronization (Vandana et al., 2014) and inclusion in cyclodextrins (Wu et al., 2006) , encapsulation in micro/nanoparticles (Zanchetta et al., 2009) , and preparation of solid dispersion (Woo et al., 2007) . Lipids based formulations, including self-emulsifying formulations, are the most promising technique for PWSD and enhance the oral absorption drugs (Liu et al., 2007) . SNEDDS are deined as the isotropic mixture of oils, solid or liquid surfactants and co-solvent/ co-surfactant that have a unique ability of forming ine oil-in-water (o/w) emulsion upon mild agitation followed by dilution in aqueous media, such as gastrointestinal (GI) luids (Khan et al., 2015) . Clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Clopidogrel also inhibits platelet aggregation induced by agonists other than ADP, by blocking the ampli ication of platelet activation due to the released ADP. However, clopidogrel does not inhibit phosphodiesterase activity. Clopidogrel acts by irreversibly modifying the platelet ADP receptor. Consequently, platelets exposed to clopidogrel are affected for the remainder of their lifespan; the oral bioavailability of clopidogrel is less than 50% due to poor water solubility. Hence the aim of this study is to be enhancing the solubility of clopidogrel by formulating into a SNEDDS (Patel et al., 2010) .
MATERIALS AND METHODS

Materials
Clopidogrel bisulfate was kindly get as a gift sample, cinnamon oil was purchased from S.D. Fine Chemicals, cold pressed sesame oil, olive oil, cotton seed oil corn oil. Tween 40, Tween 80 was purchased from Sigma Aldrich, span 80 was purchase from loba chemie, PEG 400 was purchased from sigma Aldrich, all other chemicals and materials used were of analytical grade.
Methods
Solubility studies
The solubility of clopidogrel bisulfate was determined in many oils (castor oil, cinnamon oil, sesame oil and sun lower oil), surfactants and cosurfactants (Tween 80, PEG 400, span 20 and Tween 20) an excess amount of 300 mg drug was added to each 2 ml Eppendorf tubes containing 1 ml each vehicles and the things were mixed using vortex mixer (REMI Equipment, Mumbai, India) to form a uniform mixing of drug for more than 10 mins. The tubes were centrifuged at 5000 rpm using (Eppendorf centrifuge 5415 R) for 20 mins. The supernatant was iltered through a 25 mm micron syringe ilter. Form the iltered supernatant 0.1 ml was collected and diluted with methanol. The drug was quanti ied by using UV spectroscopy method (Balakumar et al., 2013) .
Selection of oil
The selection of oil was based on the solubility of clopidogrel bisulfate in oils. Higher solubility of drug will shows the high drug loading capacity and potential. In this study, the drug was more soluble in cinnamon oil. So that was chosen as oil phase for formulating the SNEDDS system (Mohd et al., 2015) .
Selection of surfactant
The screening of surfactant was based on the ability to solubilize the drug and ability to emulsify the oil phase. The selection of surfactants was determined from solubility studies. To determine their emulsiication ability, 20μl of surfactant and 20μl of the selected oil phase was added together thoroughly mixed by using vortex in an Eppendorf tube. From this mixture 25μl of mixture was added to 25 ml distilled water in a standard lask. The formed emulsion were allowed to stand for 2 h and seen for phase separation. Then the transmittance was determined using UV spectrophotometer at 638 nm against distilled water as the blank (Kassem et al., 2016) .
Selection of co-surfactant
The screening of co-surfactant was based on both the ability to solubilize the drug in it and their ef icacy to improve the nanoemulsi ication ability of the selected surfactants. The solubility studies same as in the case of oils and surfactants. Then to screen the ef icacy of co-surfactant , 40μl of the selected surfactant and 20μl of co-surfactant to be screened and 60μl of selected oil phase were mixed together thoroughly in an Eppendrof tube. From this mixture, 25μl was added to 25 ml of distilled water in a standard lask. The ease of emulsi ication was checked in a similar fashion as described above (Kassem et al., 2016) .
Construction of pseudo-ternary phase diagram
The pseudo ternary phase diagram was constructed without using of clopidogrel bisulfate to identify the self-nanoemulsifying regions and to optimize the percentage of oil surfactant/ co-surfactant (S mix ) were mixed in different ratios and was added to oil phase in varying proportions (1:01-1:05). It was then titrated with water until the mixture turned clear. The values were then plotted in TRIDRAW1.0.0.0 software to identify the nanoemulsi ication region (Raavi et al., 2014) .
Preparation of L-SNEDDS
Twelve L-SNEDDS of clopidogrel bisulfate were formulated using oil (15, 20, 25, and 30) and S mix in the ratio of 1:1, 2:1, 3:1. The drug loaded L-SNEDDS were prepared by adding the oil phase, containing accurately weighed quantity (97.875mg) of clopidogrel bisulfate, drop wise into the S mix with constant stirring for 30 mins. It was equilibrated at ambient temperature for 48 h and investigated for signs of turbidity or phase separation. The compositions of prepared L-SNEDDS were represented inTable 1.
Emulsion droplet size and PDI analysis
The globule size of the emulsion determines the rate and extent of drug release. 1ml of the optimized SNEDDS was diluted with 100 fold of distilled water to assess the globule size using zetasizer (nano zs 90). The z-average diameter was derived from cumulated analysis by the auto-measure software (Mohd et al., 2015) .
Time for self-nanoemulsi ication
The time required for self-nanoemulsi ication of selected formulations was assessed on USP-II dissolution apparatus. Each formulation was drop wise added to 500 ml of distilled water, mild agitation was required to form nanoemulsion. That gentle agitation was provided by standard stainless-steel which was rotated at 50 rpm. Self emulsi ication time was visually observed and graded (Khan et al., 2015) Table 2 .
Stability studies
The stability studies were conducted to determine the changes in in-vitro drug release studies, drug content, emulsion droplet size and PDI on storage. This stability studies were done according to the ICH guidelines by storing the optimized SNEDDS for 3 months. After that period of 3 months the samples collected and analyzed for the previously mentioned studies (Mohd et al., 2015) .
Preparation of S-SNEDDS from L-SNEDDS
The one of the simplest technique to convert L-SNEDDS to S-SNEDDS is freeze drier. Twenty grams of L-SMEF was added to 500 ml distilled water and stirred (100rpm) for 10 min, to form homogeneous ine emulsion. Further, 10g of Aerosil200 was added to the prepared emulsion and mixed by stirring at 100rpm for 10min.Obtained emulsion was deep freeze (Thermo scienti ic) for 24 h. The Aerosil suspension thus obtained was freeze dried to remove water by sublimation methods. No lyoprotectant for freeze drying process was used as Aerosil itself had inherent properties of lyoprotectant. The lyophilizer (MINI LYODEL, DELVAC PUMPS) was operated at condenser temperature −40 • C and pressure below 15 Pascal (Singh et al., 2013) .
Solid state characterization prepared powder SNEDDS
The morphological characterization of clopidogrel 
In vitro drug release studies
Marketed tablet (75 mg dose), dose equivalent amount of clopidogrel loaded S-SNEDDS were placed in a USPBI dissolution test apparatus (LABINDIA, Mumbai, India). The dissolution test was performed using 900 ml of acidic buffer pH 2.0 as a dissolution medium. Temperature and speed of the basket were adjust to 37±0.5 • C and 50 rpm respectively, at predetermined time intervals (0, 5, 10, 15, 30, 45 and 60 min) an aliquot (5 ml) of the samples was collected and iltered through a membrane ilter at each time 5 ml of fresh medium was replaced (Jassim and Hussein, 2017) .
RESULTS AND DISCUSSION
Selection of oil
Solubility of clopidogrel in oils, surfactants and co-surfactants determination was the important principle for the selection of components for SNEDDS formulation. The solubility of clopidogrel in different oils was shown in the Figure 1 . Among all these selected oils (castor oil, cinnamon oil, sesame oil and sun lower oil) in these cinnamon oil shows higher solubility for clopidogrel so this was selected as oil phase for SNEDDS formulation. 
Selection of surfactant
Non-ionic surfactants were most preferred for oral ingestion and this was considered as safer than the ionic surfactants. These surfactants were screened based on the higher solubility of clopidogrel and also ability to emulsify the selected oil. Tween 80 showed highest solubilization capacity of clopidogrel Figure 1 so Tween-80 there chosen for further investigations.
Selection of co-surfactant
The PEG 400 shows good solubility of clopidogrel Figure 1 and also it form nanoemulsi ication ef iciency of the selected surfactant. PEG 400 was selected as the co-surfactant for further investigations.
Ternary phase diagram
The ternary phase diagram were constructed to identify the nanoemulsion region and constructed to identify the concentration selected oil, surfactant, co-surfactant. Phase diagram was constructed in the absence of clopidogrel. This phase diagram plays important role in studying the phase behavior of the formed nanoemulsion (Parmar et al., 2011; Constantinides, 1995) Figure 2 .
Optimization of L-SNEDDS
The amount of oil, surfactant, co-surfactant for the further formulation of clopidogrel SNEDDS was optimized on the basis of Z-average size and PDI. The results are shown in Table 1 . All the formulation Zaverage size was from 90 d.nm -281.6 d.nm.
Emulsion droplet size analysis
Droplet size of the emulsion de ined the rate and extent of rug release. The z-average size of the nanoemulsion was determined by 100 times dilu- 
Stability studies
Stability studies conducted to identify the temperature sensitivity of L-SNEDDS emulsion droplet size and PDI. The selected Liquid SNEDDS formulation F 7 were kept for stability testing at 30
• ± 2 • C / 65 ± 5% RH. There has no signi icant change in the emulsion droplet size and PDITable 3.
Time for self-nanoemulsi ication
SNEDDS formulation should have ability to disperse completely and quickly when subjected to dilution under mild agitation. Formulations F 3,F 4, F 7, F 8, F 11, F 12, shows very less emulsi ication time (< 1 min) when compared to others Table 4 . 75 ± 4.6 F 6 80 ± 3.9 F 7
Characterization of solid SNEDDS
Morphological analysis solid SNEDDS (SEM)
41 ± 2.6 F 8 57 ± 2.9 F 9 79 ± 4.0 F 10 82 ± 4.5 F 11 52 ± 3.1 F 12 60 ± 3.0
The scanning electron microscopy picture of solid SNEDDS formulations were presented inFigure 4ap-peared as smooth surfaced, irregular shaped crystals. 
In vitro drug release studies
The dissolution pro ile of solid SNEDDS and marketed formulations were compared, using acetate buffer pH 2.0 as a dissolution medium. Marketed formulation shows 50% of the drug released within 20 mins. The solid SNEDDS shows 75% of drug released within 15 mins. This result indicates that the spontaneous nano emulsion was formed and drug has been released Figure 5 . 
CONCLUSION
The present study concludes that the formulation of poorly water soluble drug clopidogrel in SNEDDS is useful for enhancing the invitro dissolution rate enhancement. The solid SNEDDS formulation F 7 shows good nanosize droplets, zeta potential and PDI values. Freeze dried F 7 formulation with Aerosil 200 as adsorbent shows 0.5 fold increased rate of dissolution when compare to marketed clopidogrel formulation.
